The U.S. FDA approved Amgen's Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to AstraZeneca's Soliris (eculizumab) for treating two rare diseases.
The approvals align with the indications currently approved for Soliris, which was first approved in 2007. PNH and aHUS are characterized by the breakdown of red blood cells. PNH results in anemia, blood clots, low blood cell counts, and dark urine, while aHUS results in anemia, low platelets, and kidney failure. Bkemv, a monoclonal antibody, binds to the complement C5 protein, inhibiting the complement system and preventing the breakdown of red blood cells in PNH and aHUS patients.
Bkemv is the 53rd approved biosimilar in the U.S., with 13 approved as interchangeable biosimilars. An interchangeable biosimilar can be substituted for the reference product without consulting the prescriber, subject to state pharmacy laws, similar to generic drug substitution for brand-name drugs.
Recently, the FDA also approved AstraZeneca's voydeya as an add-on to the standard-of-care — Ultomiris or Soliris — to address the needs of the approximately 10-20% of patients with PNH who experienced clinically significant extravascular hemolysis (EVH) while treated with a C5 inhibitorC5 inhibitor. For some patients, EVH, which is the destruction of red blood cells outside of the blood vessels, resulted in continued symptoms of anemia and may require blood transfusions.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.